Analysts expect Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) to announce earnings of ($0.66) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Trillium Therapeutics’ earnings. The lowest EPS estimate is ($0.78) and the highest is ($0.59). Trillium Therapeutics reported earnings per share of ($0.72) during the same quarter last year, which would suggest a positive year over year growth rate of 8.3%. The business is scheduled to issue its next earnings results on Friday, March 8th.
On average, analysts expect that Trillium Therapeutics will report full-year earnings of ($2.47) per share for the current fiscal year, with EPS estimates ranging from ($2.52) to ($2.42). For the next financial year, analysts anticipate that the company will report earnings of ($2.04) per share, with EPS estimates ranging from ($2.43) to ($1.34). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Trillium Therapeutics.
Several research firms have recently issued reports on TRIL. Zacks Investment Research lowered shares of Trillium Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. HC Wainwright set a $10.00 target price on shares of Trillium Therapeutics and gave the stock a “buy” rating in a report on Thursday, November 15th.
Trillium Therapeutics stock opened at $3.01 on Monday. The stock has a market capitalization of $44.21 million, a PE ratio of -0.85 and a beta of 2.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.33 and a quick ratio of 4.33. Trillium Therapeutics has a 12-month low of $2.28 and a 12-month high of $11.70.
Several institutional investors have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP lifted its holdings in shares of Trillium Therapeutics by 25.0% in the 2nd quarter. Baker BROS. Advisors LP now owns 511,763 shares of the biotechnology company’s stock worth $3,071,000 after acquiring an additional 102,440 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Trillium Therapeutics by 25.2% in the 3rd quarter. Morgan Stanley now owns 356,655 shares of the biotechnology company’s stock worth $2,068,000 after acquiring an additional 71,860 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Trillium Therapeutics by 245.3% in the 2nd quarter. Renaissance Technologies LLC now owns 144,000 shares of the biotechnology company’s stock worth $864,000 after acquiring an additional 102,300 shares during the last quarter. Stanley Laman Group Ltd. lifted its holdings in shares of Trillium Therapeutics by 26.7% in the 2nd quarter. Stanley Laman Group Ltd. now owns 137,091 shares of the biotechnology company’s stock worth $823,000 after acquiring an additional 28,907 shares during the last quarter. Finally, Wealth Alliance Advisory Group LLC bought a new stake in shares of Trillium Therapeutics in the 3rd quarter worth about $126,000. Hedge funds and other institutional investors own 47.74% of the company’s stock.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
Further Reading: When is a capital gain realized?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.